The present invention is directed to an oligonucleotide comprising a nucleic acid sequence of SEQ ID No. 1 or parts thereof, wherein 1 to 4 nucleotides at the 3′-end and/or at the 5′-end of the oligonucleotide are modified at a base, a sugar and/or a phosphate for use in a method of reducing or inhibiting of scarring, of fibrotic closure of the trabeculectomy canal, of epithelial-to-mesenchymal transition of the trabecular meshwork and/or providing of protecting activity of the optic nerve optionally the optic nerve head. Further, the present invention refers to a pharmaceutical composition comprising such oligonucleotide and a pharmaceutically acceptable carrier.

Provided are compositions that include an effective amount of a peptide or polypeptide derived from a Bordetella ACT AC domain, optionally wherein the peptide or polypeptide is 80-100% identical to an amino acid sequence as set forth in SEQ ID NOs: 1-5 and 44-53. Also provided are methods of using the same for preventing and/or treating a diseases, disorders, and conditions associated with the presence and/or development of biofilm; and for reducing the incidence of nosocomial infections; for inhibiting biofilm development and/or for reducing or eliminating biofilm present on medical, dental, and industrial surfaces.

Provided are compositions that include an effective amount of a peptide or polypeptide derived from a Bordetella ACT AC domain, optionally wherein the peptide or polypeptide is 80-100% identical to an amino acid sequence as set forth in SEQ ID NOs: 1-5 and 44-53. Also provided are methods of using the same for preventing and/or treating a diseases, disorders, and conditions associated with the presence and/or development of biofilm; and for reducing the incidence of nosocomial infections; for inhibiting biofilm development and/or for reducing or eliminating biofilm present on medical, dental, and industrial surfaces.

Methods for enhancing or accelerating osseointegration of an implant into bone marrow of a subject, the methods comprising increasing expression of peripheral clock neuronal PAS domain protein 2 (NPAS2) in the bone marrow, are provided. Expression of NPAS2 is increased by administration of a Npas2 modulating compound to the subject.

Disclosed herein are pharmaceutical compositions useful for the treatment and prevention of adhesions and ileus.

Disclosed herein are pharmaceutical compositions useful for the treatment and prevention of adhesions and ileus.

The present disclosure provides methods and compositions for the treatment of hepatic symptoms of glycogen storage diseases through the administration of thyroid hormone receptor agonists. The methods and compositions provided herein are useful in the treatment of hyperlipidemia, hypercholesterolemia, hepatic steatosis, cardiomegaly, hepatomegaly, hepatic fibrosis, and cirrhosis associated with glycogen storage diseases (GSD) and defects of glycogen metabolism. Said compounds may also be useful in the prevention of GSD-related hepatocellular adenoma and hepatocellular carcinoma.

The present disclosure provides methods and compositions for the treatment of hepatic symptoms of glycogen storage diseases through the administration of thyroid hormone receptor agonists. The methods and compositions provided herein are useful in the treatment of hyperlipidemia, hypercholesterolemia, hepatic steatosis, cardiomegaly, hepatomegaly, hepatic fibrosis, and cirrhosis associated with glycogen storage diseases (GSD) and defects of glycogen metabolism. Said compounds may also be useful in the prevention of GSD-related hepatocellular adenoma and hepatocellular carcinoma.

The disclosure provides methods of treating pain in a patient who will be subjected to a surgical procedure, comprising administering meloxicam to the patient prior to start of the surgical procedure. In some embodiments, meloxicam is nanocrystalline meloxicam. The disclosure further provides methods of treating pain in a patient in need thereof, comprising administering meloxicam intravenously to the patient in combination with acetaminophen and/or gabapentin.

The disclosure provides methods of treating pain in a patient who will be subjected to a surgical procedure, comprising administering meloxicam to the patient prior to start of the surgical procedure. In some embodiments, meloxicam is nanocrystalline meloxicam. The disclosure further provides methods of treating pain in a patient in need thereof, comprising administering meloxicam intravenously to the patient in combination with acetaminophen and/or gabapentin.